Article
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
British journal of haematology - 1 Mar 2021
Tiong Ing S, Dillon Richard, Ivey Adam, Teh Tse-Chieh, Nguyen Phillip, Cummings Nicholas, Taussig David C, Latif Annie-Louise, Potter Nicola E, Runglall Manohursingh, Russell Nigel H, Raj Kavita, Schwarer Anthony P, Fong Chun Yew, Grigg Andrew P, Wei Andrew H
Abstract excerpt
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.